Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Stephen Baxter maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $103 t...
Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India t...
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready ...
Pete Buttigieg says Trump's ATC attack is a distraction from his "bad deal" on health insurance and failure on "...
Health insurer stocks fell after the Senate ended the shutdown without extending ACA subsidies, delaying the decision to Decemb...
https://trumpstruth.org/statuses/33744
TD Cowen analyst Charles Rhyee maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $99 to $100.
